$1.65
+0.25 (+18.28%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ACXP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 1.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile InfectionNCT07513285Evaluate the rate of CDI Clinical Cure (CC)Open-label · Treatment | Phase 2 | Recruiting | Drug: Ibezapolstat | Clostridium Difficile Infection Recurrence | 20 | 2027-09-29 | in 406 d | 2026-08-12 |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542results2025-01-17Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) PopulationRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ibezapolstat, Vancomycin | Clostridium Difficile Infection | 53 | 2023-10-03actual | — | 2025-01-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19